EVALUATION OF CYP2C9 ACTIVITY BY LOSARTAN TEST TO OPTIMIZETHE ANTICOAGULANT WARFARIN THERAPY IN PATIENTS AFTER HEART VALVE REPLACEMENT

Formation of an effective strategy for managing patients after implantation of an artificial heart valve (АНV), in order to prevent
thrombotic complications is an important problem in cardiology. The use of indirect anticoagulants, including warfarin reduces the potential
of the blood coagulation and «extinguish» the response of the hemostatic system to the presence of a foreign body in the active blood flow.
Identification the relative contributions of genetic polymorphisms with the definition of CYP2C9 activity can help in personalizion of warfarin
dosing in patients after implantation of АНV.

S.M. Arslanbekova (1), D.A. Sychev (2,3), E.Z. Golukhova (1)
1 -Scientific Center of Cardiovascular Surgery named after A.N. Bakulev, RAMS; 2 -FSBI «SCEMAP» of the Ministry of Health of the Russian Federation; 3 -Department of Clinical Pharmacology, Sechenov’s First Moscow State Medical University, Moscow, Russia